BIO-Europe Spring® 2016: ReViral sets out clinical data timeline for RSV therapy

April 28, 2016
Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, chats with chief financial officer of ReViral Ltd., Max Herrmann, about the company's long-standing expertise in antiviral development and plans for the future. Recently RiViral managed to raise USD 21 million in a series A financing round that Herrmann explains will be spent on IND-enabling studies, first human studies and proof-of-concept trials for its leading RSV (respiratory syncytial virus) antiviral therapies.
Previous Video
BIO-Europe Spring® 2016: PledPharma seeks partner for lead therapy
BIO-Europe Spring® 2016: PledPharma seeks partner for lead therapy

Jacques Näsström, CEO of Pled Pharma, chats with Sten Stovall, senior editor at Pharma Intelligence, about ...

Next Video
BIO-Europe Spring® 2016: Affibody CEO describes three-year growth plan
BIO-Europe Spring® 2016: Affibody CEO describes three-year growth plan

Sten Stovall chats with David Bejker, CEO of Solna, Sweden-based biotech Affibody AB, about development pro...